Healthcare Stock Winners: Which Medical Stocks Are Outperforming in 2026?

The healthcare sector continues to attract investor attention, with certain medical stocks demonstrating exceptional performance relative to their industry counterparts. Among the standout performers, BrightSpring Health Services, Inc. (BTSG) has captured the spotlight, but what makes specific medical stocks worth watching?

BTSG Shows Strong Momentum Among Medical Stocks

BrightSpring Health Services, Inc. remains a compelling case study for investors tracking healthcare equities. The company has garnered a Zacks Rank #1 (Strong Buy) designation, signaling strong confidence from analysts tracking the sector. What’s particularly noteworthy is that analyst consensus on BTSG’s full-year earnings has climbed 8.2% over the past quarter—a clear indicator of improving sentiment toward the company’s financial prospects.

Performance-wise, BTSG has delivered year-to-date gains that significantly exceed the medical sector average. While the broader Medical group has averaged approximately 1% returns, BrightSpring has surged ahead with double-digit gains. This divergence highlights why medical stocks demonstrating genuine earning momentum often outpace their peers. Such outperformance doesn’t happen in isolation; it reflects strengthening business fundamentals and growing investor confidence in the company’s trajectory.

Why Earnings Expectations Matter for Medical Stocks

The Zacks evaluation framework emphasizes earnings estimates and their revisions as critical indicators for identifying medical stocks poised for outperformance. This methodology has proven effective at identifying winners within the healthcare space. When analysts collectively raise their earnings forecasts—as seen with BTSG’s recent upward revision—it typically signals that the market has underpriced the opportunity.

C4 Therapeutics, Inc. (CCCC) provides another compelling example in this category. This biomedical firm has experienced even more dramatic gains, with shares climbing 61.8% year-to-date. Similarly impressive, consensus EPS estimates for CCCC have increased 16.8% over the past three months, landing the stock a Zacks Rank #2 (Buy) rating. This pattern—strong earnings momentum coupled with significant share price appreciation—is a hallmark of high-performing medical stocks.

Comparing Industries: A Closer Look at Performance

The distinction between individual stock performance and broader industry trends reveals important nuances for healthcare investors. BrightSpring operates within the Medical Services industry, a sector containing 66 companies currently ranked #92 among Zacks-tracked industries. This particular group has declined approximately 2.9% year-to-date, making BTSG’s outperformance even more impressive—the stock is swimming against sector headwinds.

Conversely, C4 Therapeutics belongs to the Medical - Biomedical and Genetics sector, a much larger industry comprising 445 stocks and ranked #133 overall. This industry has gained 8% year-to-date, providing a more favorable backdrop for its constituents. The contrast illustrates a key principle for medical stocks investors: industry tailwinds can amplify or dampen individual company performance.

What This Means for Healthcare Investors

Both BTSG and CCCC exemplify why tracking earnings momentum remains essential when evaluating medical stocks. The combination of improving analyst sentiment, strong earnings revisions, and outperformance relative to peers suggests these positions warrant continued attention from healthcare-focused portfolios. As the medical sector continues to evolve, staying alert to which medical stocks are delivering both earnings growth and relative outperformance will remain a cornerstone of successful healthcare investing.